ArticleJournal of animal science and technology2026
Characteristics between porcine bone marrow-derived mesenchymal stem and peripheral blood mononuclear cells.
Article in Journal of animal science and technology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mesenchymal stem cells (MSCs) have been isolated from various organs and extensively studied for their potential in regulating transplantation. MSCs from different mammalian species are well characterized; however, the properties and therapeutic potential of porcine bone marrow-derived MSCs (BM-MSCs) remain unclear. In this study, we aimed to profile the characteristics of porcine BM-MSCs by comparing their gene expression patterns and immunomodulatory properties with those of porcine peripheral blood mononuclear cells (PBMCs) and bone marrow-attached cells (BMACs). Using quantitative polymerase chain reaction, flow cytometry, immunocytochemistry, and RNA sequencing, we confirmed the expression of key MSC markers, including CD105, CD73, and CD90, in porcine BM-MSCs, and aligned them closely with human MSCs. We found significant differences in gene expression between BM-MSCs and PBMCs, with BM-MSCs exhibiting a distinct expression pattern similar to that of BMACs. Gene ontology enrichment analysis revealed the pathways involved in immune modulation and tissue repair, underscoring the potential of BM-MSCs to enhance immune regulation. Notably, BM-MSCs exhibited higher transforming growth factor-beta levels than PBMCs, suggesting a central role in their immunosuppressive function. These findings indicate the immunomodulatory capabilities of porcine BM-MSCs and support their application in xenotransplantation, where they may help mitigate graft rejection and promote tissue regeneration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.